Human NKp44/NCR2 Antibody

Catalog #: MAB22491
7 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB22491
MAB22491-SP

Human NKp44/NCR2 Antibody Induces IFN-gamma Secretion in Activated Human NK Cells.

1 Image

All NKp44/NCR2 Antibodies

Product Details

Citations (7)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human NKp44/NCR2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human NKp44/NCR2 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) NKp30, rhNKp46, rhNKp80, or recombinant mouse NKp46 is observed.

Source

Monoclonal Mouse IgG_2A Clone # 253415

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human NKp44/NCR2
Gln22-Pro190
Accession # CAB52289

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Flow Cytometry

2.5 µg/10⁶ cells

Human CD56⁺ peripheral blood mononuclear cells treated with Recombinant Human IL‑2 (Catalog # 202-IL)

Agonist Activity

0.05-0.2 µg/mL

See below

CyTOF-reported

Gaudilliere, B. et al. (2014) Sci. Transl. Med. 6: 255ra131. Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Agonist Activity

Human NKp44/NCR2 Antibody Induces IFN-? Secretion antibody in Activated Human NK Cells.

View Larger

Human NKp44/NCR2 Antibody Induces IFN-gamma Secretion in Activated Human NK Cells. Mouse Anti-Human NKp44/NCR2 Monoclonal Antibody (Catalog # MAB22491) induces IFN-gamma secretion in human natural killer (NK) cells activated with 500 ng/mL Recombinant Human IL-2 (Catalog # 202-IL), in a dose-dependent manner, as measured using the Human IFN-gamma DuoSet ELISA Kit (Catalog # DY285B). The ED₅₀ for this effect is typically 0.05-0.2 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: NKp44/NCR2

NKp44, along with NKp30 and NKp46, constitute a group of receptors termed "Natural Cytotoxicity Receptors" (NCR) (1). These receptors are expressed almost exclusively by NK cells and play a major role in triggering NK-mediated killing of most tumor cell lines. No rodent ortholog to NKp44 has been identified. Human NKp44, also known as NCR2, is a 44 kDa type I transmembrane glycoprotein that is characterized by the presence of one extracellular V-like immunoglobulin domain (2). It is synthesized as a 276 amino acid (aa) precursor that contains a 21 aa signal sequence, a 171 aa extracellular region, a 21 aa transmembrane segment and a 63 aa cytoplasmic tail. Alternate splicing in both the cytoplasmic tail and extracellular region generates multiple isoforms of unknown significance. The Ig-like region is unaffected. A physical association with the ITAM-bearing accessory protein, DAP12, occurs via a charged residue in the NKp44 transmembrane domain. Ligation of NKp44 with a specific antibody results in phosphorylation of DAP12 (3) and activation of target cell lysis in a redirected killing assay (4). NKp44 is absent from resting NK cells but is upregulated upon activation with IL-2. Activation-induced expression occurs in the CD56^dim CD16⁺ NK subset that accounts for more than 85% of NK cells found in peripheral blood and spleen, as well as the CD56^bright CD16^- NK subset that constitutes the majority of NK cells in lymph node and tonsil (5). Studies with neutralizing antibodies reveal that NKp44 is partially responsible for triggering lytic activity against several tumor cell types (2, 6). Blocking any of the individual NCRs results in partial inhibition of tumor cell lysis, but nearly complete inhibition of lysis is observed if all three receptors are blocked simultaneously (6). NKp44 has also been implicated in recognition of virus-infected cells through its capacity to bind to viral hemagglutinins (7).

References

Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
Cantoni, C. et al. (1999) J. Exp. Med. 189:787.
Augugliaro, R. et al. (2003) Eur. J. Immunol. 33:1235.
Vitale, M. et al. (1998) J. Exp. Med. 187:2065.
Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
Pende, D. et al. (1999) J. Exp. Med. 190:1505.
Arnon, T. et al. (2001) Eur. J. Immunol. 31:2680.

Long Name

NK Cell Activating Receptor

Entrez Gene IDs

9436 (Human); 102129442 (Cynomolgus Monkey)

Alternate Names

CD336 antigen; CD336; LY95; LY95lymphocyte antigen 95 homolog (activating NK-receptor; NK-p44); lymphocyte antigen 95 (activating NK-receptor; NK-p44); Lymphocyte antigen 95 homolog; natural cytotoxicity triggering receptor 2; Natural killer cell p44-related protein; NCR2; NK cell activating receptor (NKp44); NK cell-activating receptor; NKp44; NK-p44dJ149M18.1

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human NKp44/NCR2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

7 Citations: Showing 1 - 7
Filter your results:

Filter by:

Poly(I:C) enhances mesenchymal stem cell control of myeloid cells from COVID-19 patients
Authors: Luciana Souza-Moreira, Yuan Tan, Yan Wang, Jia-Pey Wang, Mahmoud Salkhordeh, Jennifer Virgo et al.
iScience
Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30
J Mol Biol, 2016-09-20;0(0):.
Species: Mouse
Sample Types: Whole Cells
Applications: Flow Cytometry
Regulation of NK92-MI cell cytotoxicity by substance P.
Authors: Fu WX, Qin B, Zhou AP, Yu QY, Huang QJ, Liang ZF
Scand. J. Immunol., 2011-08-01;74(2):107-13.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells.
Authors: Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, Porgador A
J. Immunol., 2009-07-27;183(4):2610-21.
Species: Human
Sample Types: Whole Cells
Applications: Functional Assay
NKp44 expression, phylogenesis and function in non-human primate NK cells.
Authors: De Maria A, Ugolotti E, Rutjens E, Mazza S, Radic L, Faravelli A, Koopman G, Di Marco E, Costa P, Ensoli B, Cafaro A, Mingari MC, Moretta L, Heeney J, Biassoni R
Int. Immunol., 2009-01-15;21(3):245-55.
Species: Human, Primate - Pan troglodytes (Chimpanzee)
Sample Types: Whole Cells
Applications: Functional Assay
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Authors: Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B, van Rhee F
Blood, 2007-10-18;111(3):1309-17.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Chronic Inflammation Permanently Reshapes Tissue-Resident Immunity in Celiac Disease
Authors: Toufic Mayassi, Kristin Ladell, Herman Gudjonson, James E. McLaren, Dustin G. Shaw, Mai T. Tran et al.
Cell